drugset / Trial / NCT05434312
TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients
Phase 1
Active not recruiting
90 enrolled
Shenzhen TargetRx Co., Ltd.
Peking University People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this single- arm, open-lable, dose escalation + dose expansion study is to evalulate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.
Timeline
- Start
- 2021-03-29
- Primary completion
- 2026-03
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TGRX-678 | Unknown | — | Oral |